The search "what is PT-141" usually comes from people who have run into the names bremelanotide, Vyleesi or melanotan and want to understand it without the marketing noise: what this molecule is, how it acts, what the studies actually showed and how reliable those data are. Below is a restrained scientific review built on published sources, not on anonymous "internet reviews".

Important. This article is purely educational. Bremelanotide in powder form, offered by suppliers, is a research substance for laboratory use, not a medicine. The only approved drug based on it (Vyleesi) is prescription-only and used strictly on a physician's prescription. As a matter of principle we do not publish invented reviews, schemes for self-administration or promises of a result.

What PT-141 is

PT-141 is the research and historical name for bremelanotide, a synthetic cyclic peptide (a heptapeptide). It belongs to the class of melanocortin receptor agonists and is structurally related to melanotan II: in essence PT-141 is its active metabolite, in which the "tanning" (pigment) action is weakened, while the effect on the neural pathways linked to sexual desire is retained.

The key difference from the usual potency agents, PDE-5 (phosphodiesterase type 5) inhibitors like sildenafil, is that bremelanotide acts not on the blood vessels but on the central nervous system: at the level of desire (libido) rather than at the level of tissue blood flow. That is why it was studied primarily as an agent against reduced sexual desire rather than purely erectile dysfunction. A full structured description, class, amino-acid sequence, CAS number (a substance's unique registry number), molar mass, half-life, we have collected in a separate PT-141 scientific monograph.

How it works

The melanocortin system is a family of receptors (from MC1R to MC5R) and their ligands that regulate pigmentation, inflammation, energy metabolism and, as studies have shown, certain aspects of sexual behavior. For bremelanotide's effect on sexual desire the key receptor is considered to be MC4R, widely present in the hypothalamus and other brain regions.

According to the available data, activation of these receptors in zones involved in motivation and arousal, primarily the medial preoptic area of the hypothalamus, modulates the dopaminergic pathways responsible for desire. In other words, the mechanism works "from the top", at the level of neural regulation, rather than through a direct effect on the blood vessels. This is a fundamental difference from vascular-acting drugs and explains why bremelanotide ended up in a separate therapeutic niche.

What the studies showed

The study of PT-141 has two stages.

Early stage (men, erectile function). The first clinical works assessed the pharmacokinetics, safety and effect of the peptide in men, including those with an inadequate response to sildenafil. Both intranasal and subcutaneous forms were studied. These studies mostly had small samples and gave a "signal" of an effect rather than firm proof. Development of the intranasal form for erectile dysfunction was later stopped, because of a rise in blood pressure at higher doses.

Later stage (women, reduced libido). The program was refocused on hypoactive sexual desire disorder (HSDD) in women. A dose-finding study confirmed the effect and defined an acceptable range, and the culmination was two identical randomized placebo-controlled phase III studies, the RECONNECT program, in premenopausal women with acquired generalized HSDD. They showed a statistically significant improvement compared with placebo on the co-primary endpoints: the desire domain of the FSFI questionnaire and the associated-distress score on the FSDS-DAO. A separate study assessed long-term safety with continued use.

It was on this evidence base that in 2019 the FDA (US Food and Drug Administration) approved the brand Vyleesi, a low-dose subcutaneous injection for the treatment of HSDD in premenopausal women. This is an important detail: the drug is approved for a specific indication and a specific population, not "for libido in general".

How reliable the data are, honestly about the level of evidence

Here it is worth being honest, because there is a lot of exaggeration around peptides.

  • For female HSDD the evidence base is relatively firm: this is a regulator-approved agent with two confirmatory phase III RCTs (randomized controlled trials) and a separate safety study.
  • But the effect is moderate. The improvement in RECONNECT was statistically significant, yet small in absolute magnitude, and it has to be weighed against the adverse events.
  • The most common problem is nausea. It occurred often and not rarely became a reason for discontinuation. Also described were flushing, headache, injection-site reactions, a transient rise in blood pressure and a fall in heart rate, and with repeated use, focal hyperpigmentation of the skin or gums.
  • For men and other scenarios quality confirmatory studies are lacking; the early works were small.

So "PT-141 works" is a correct statement only within the studied indication and only about the approved drug, not a universal promise.

Research substance versus medicine

It is important not to confuse two different things. The approved drug is a standardized, quality-controlled prescription product with a proven profile. Research bremelanotide is a reagent for laboratory experiments: it does not undergo pharmaceutical control of dosing and purity at the level of a medicine and is not intended for human use.

If you work with the peptide in a research context, the transparency of origin and analytics matters. Our research PT-141 (bremelanotide) by Longeva is supplied as a lyophilized powder with an accompanying certificate of analysis (COA), for laboratory research only. For a deeper dive into the pharmacology, see the PT-141 monograph, where references to primary sources with real DOIs are collected.

PT-141 and melanotan, what is the difference

Since bremelanotide is derived from melanotan II, the two are often confused. Melanotan II is a non-selective melanocortin agonist that historically interested researchers primarily because of its effect on pigmentation (darkening of the skin). PT-141 is its "descendant" with a different emphasis: the pigment component in it is weakened, while the effect on the neural pathways of desire comes to the fore. So these are different molecules with different profiles, and data on one cannot be automatically transferred to the other. Likewise, one should not equate a research powder with an approved drug: the name of the active substance is the same, but these are objects with a different purpose and different quality control.

Frequently asked questions

Is this a "potency agent" like Viagra? Not quite. PDE-5 inhibitors improve blood flow, while bremelanotide affects the central mechanisms of desire, these are different targets, and the approved indication concerns specifically reduced libido in women, not erectile function.

Can it be bought as a medicine? The approved drug (Vyleesi) is prescription-only. Powder from suppliers of research substances is not a medicine and is sold only for laboratory use.

How strong is the effect? Per the RCT (randomized controlled trial) data, statistically significant but moderate, and it has to be weighed against the frequent adverse events, primarily nausea.

In brief

  • PT-141 (bremelanotide) is a cyclic peptide, a melanocortin receptor (MC4R) agonist that acts on the central neural pathways of sexual desire.
  • This distinguishes it from vascular-acting ED (erectile dysfunction) drugs.
  • For female HSDD there are two phase III RCTs (RECONNECT) and FDA approval (Vyleesi, 2019); the effect is moderate, and nausea is common.
  • For other scenarios there are far fewer data.
  • Powder from suppliers is a research substance, not a medicine; any clinical use is only through an approved prescription drug and a physician.

The material is educational and is not medical advice or a guide to use. Research substances are intended for laboratory research only.